3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
58
130-nm albumin-bound paclitaxel
35
Specimen Handling
26
Fluorouracil
22
Albumin-Bound Paclitaxel
22
Magnetic Resonance Spectroscopy
21
Leucovorin
21
Irinotecan
21
Oxaliplatin
19
Biopsy
17
Taxes
16
pembrolizumab
15
Cyclophosphamide
12
Cisplatin
11
fludarabine
10
Cetuximab
9
Capecitabine
8
durvalumab
7
Radiosurgery
7
Nivolumab
7
Carboplatin
7
irinotecan sucrosofate
6
dehydroftorafur
6
Pemetrexed
6
olaparib
5
Radiotherapy
5
Ipilimumab
5
Erlotinib Hydrochloride
5
Blood Specimen Collection
5
trastuzumab deruxtecan
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
tisotumab vedotin
×
90 days
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled